Blacklisting Over Failed Drug Samples Quashed: Supreme Court

Blacklisting Over Failed Drug Samples Quashed Where Mandatory Re-Test Was Skipped and Batches Expired: Supreme Court

Published: 30 October 2026 · NyayVidhan

The Supreme Court has quashed orders of the M.P. Public Health Services Corporation that blacklisted drug supplier M/s JPEE Drugs for three years and debarred it from supplying one product for two years after samples were reported not of standard quality. The tender's mandatory second-laboratory test was never done, the High Court's re-testing direction went uncomplied and the batches have expired, so the firm irretrievably lost the chance to dispute the reports (paras 8, 24-27).

Key holdings

Clause 6 of Annexure IX to the Tender Document required a second sample to be tested by another laboratory before blacklisting; admittedly it was not followed (paras 19, 24).

Once the High Court found that flaw, it should not have made the orders' fate depend on fresh test reports (paras 19, 28).

The Medipol principle on losing the chance of re-testing applies to blacklisting and debarment, not only to prosecutions (paras 25-26).

The uncomplied re-testing direction and the expiry of all four batches made the firm's loss of opportunity irretrievable (paras 22-23, 26).

Judgment digest by NyayVidhan: a summary of the court's judgment, not its text. The judgment itself is the authoritative version.

Brief Facts

M/s JPEE Drugs, a licensed manufacturer and supplier, won a tender to supply Ascorbic Acid (Vitamin C) and Ethambutol Hydrochloride tablets to Madhya Pradesh government hospitals through the M.P. Public Health Services Corporation Limited (MPPHSCL) (para 4). After four batches were reported Not of Standard Quality, a show-cause notice of 23.09.2024 proposed blacklisting (paras 5-6). On 30.09.2024 the Managing Director, recording that no reply had been received, debarred the firm for two years from supplying Ethambutol, blacklisted it for three years from MPPHSCL tenders and directed deposit of the batch values; an order of 01.10.2024 rejected its representation (paras 7-9). The High Court ordered re-testing but did not quash the orders (paras 10, 20, 28).

Court's Findings

The Court noted that the High Court had itself found the orders flawed because Clause 6 of Annexure IX to the Tender Document, a mandatory requirement, was not followed: a second sample from the same batch had to be tested by another laboratory before blacklisting. Having so found, the High Court was not justified in deferring the quashing until fresh test reports arrived (paras 13, 19, 24). Its 15-day direction for fresh samples was still uncomplied over six months later, when this Court stayed the blacklisting on 26.05.2026, and all four batches have since expired, so the re-testing direction stands frustrated by efflux of time (paras 20-23). The Court relied on Medipol Pharmaceutical: where delay predominantly attributable to the State causes the loss of an effective opportunity to have a sample retested by a superior laboratory, adverse action founded on the disputed analysis cannot be sustained, a principle reflected in Section 25(3) and (4) of the Drugs and Cosmetics Act, 1940 (para 25). It held the principle fully applies to administrative and contractual action, as blacklisting and debarment carry serious civil consequences; the procedural infirmity and the irretrievable loss of re-testing made the orders unsustainable (para 26).

Legal Principle

Where a tender makes a second-laboratory test mandatory before blacklisting for quality failure, a supplier cannot be blacklisted or debarred on the first adverse report alone. If the batches expire before any re-test and the chance to dispute the report is lost, adverse action founded on that report cannot be sustained (paras 24-26).

NyayVidhan's view · Practice note

Why It Matters

For drug suppliers to state health corporations, and the officers who act on failed samples, this ruling makes a tender's re-testing clause a real safeguard. Where the tender requires a second sample from the same batch to be tested by another laboratory before blacklisting, that test must come before the blacklisting, not after (paras 24, 26). Time matters too: medicines expire, and once the chance to re-test is lost, a later re-testing order cannot save the action (paras 23, 26). Compare Awadhesh Singh Gautam, on recovery from a contractor's bills without the hearing its contract required.

Editorial comment by the NyayVidhan Editorial Desk. It is not part of the Court's judgment and is not legal advice.

Precedents Relied Upon

Medipol Pharmaceutical India Pvt. Ltd. v. Post Graduate Institute of Medical Education & Research (2021) 11 SCC 339
Applied Discussed at ¶ 25, 26
Held that where delay predominantly attributable to the State or its instrumentalities results in the loss of an effective opportunity to have a drug sample retested by a superior laboratory, adverse action founded on the disputed analysis cannot be sustained; the Court extracted a passage from it and applied the principle to the blacklisting and debarment of a drug supplier, though they arose from administrative and contractual action and not a prosecution.
Medicamen Biotech Ltd. v. Rubina Bose, Drug Inspector (2008) 7 SCC 196
Referred To Discussed at ¶ 25
One of the decisions considered in Medipol which, the Court said, underscore the importance of preserving an effective opportunity to have a disputed drug sample tested by a superior laboratory.
Laborate Pharmaceuticals India Ltd. v. State of Tamil Nadu (2018) 15 SCC 93
Referred To Discussed at ¶ 25
One of the decisions considered in Medipol which, the Court said, underscore the importance of preserving an effective opportunity to have a disputed drug sample tested by a superior laboratory.